Tag: glucagon-like peptide 1 (GLP-1) receptor agonists
Study: Ozempic slows disease, reduces cardiovascular risk in CKD, diabetes patients
Editor's Note Semaglutide, the active ingredient in Ozempic diabetes treatment and Wegovy weight-loss treatment, outperformed a placebo and demonstrated capacity to reduce risk of death from kidney-related or cardiovascular causes in a recent study of patients with type 2 diabetes and chronic kidney disease spearheaded by manufacturer Novo Nordisk. Published…
Study: Weight-loss drug semaglutide boosts repeat surgery risk
Editor's Note Popular weight-loss \ drug semaglutide could significantly increase risk for repeat operations patients with diabetes who undergo lumbar surgery. According to a May 8 report in Medscape Medical News, the findings are pending review for publication and reportedly provides the first evidence on the impact of semaglutide on…
Free Daily News
- Study: Education, exercise improve knee OA with or without prior surgery
- Study: Early surgery outperforms endoscopy for long-term pancreatitis
- Study: Blood thinner, NSAID combination raises bleeding risk
- Hospital financial report predicts stability, high cybersecurity costs for 2025
- IV fluid shortage drives innovation in hospital hydration practices
- FDA Class 1 recalls target anesthesia workstations, ambulatory infusion pumps, ventilators
- Five leadership lessons from an ASC CEO
- CMS final rule for CY 2025: Key updates impacting Medicare payments, quality programs
- GAO urges HHS to strengthen cybersecurity oversight
- Study: GLP-1s reduce TKA complications for non-diabetic patients with obesity
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement